KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Tax Provisions (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Tax Provisions for 12 consecutive years, with $2.2 million as the latest value for Q4 2025.

  • Quarterly Tax Provisions fell 80.09% to $2.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$10.4 million through Dec 2025, down 143.66% year-over-year, with the annual reading at -$10.5 million for FY2025, 143.66% down from the prior year.
  • Tax Provisions for Q4 2025 was $2.2 million at Supernus Pharmaceuticals, up from -$12.8 million in the prior quarter.
  • The five-year high for Tax Provisions was $25.9 million in Q3 2023, with the low at -$16.3 million in Q2 2023.
  • Average Tax Provisions over 5 years is $1.7 million, with a median of $2.8 million recorded in 2022.
  • The sharpest move saw Tax Provisions crashed 571.23% in 2023, then skyrocketed 7586.39% in 2024.
  • Over 5 years, Tax Provisions stood at -$391000.0 in 2021, then surged by 2570.33% to $9.7 million in 2022, then crashed by 101.52% to -$147000.0 in 2023, then surged by 7586.39% to $11.0 million in 2024, then plummeted by 80.09% to $2.2 million in 2025.
  • According to Business Quant data, Tax Provisions over the past three periods came in at $2.2 million, -$12.8 million, and -$5.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.